Alterity Therapeutics (ATHE) Receivables (2017 - 2025)

Alterity Therapeutics has reported Receivables for 9 years, with the latest figure at $2.5 million in Q2 2025.

• For the quarter ending Q2 2025, Receivables fell 5.32% year-over-year to $2.5 million; the trailing twelve-month figure through Jun 2025 stood at $2.5 million (down 5.32% YoY), and the FY2025 full-year result was $2.5 million, down 5.32% from the prior year.
• Receivables for Q2 2025 stood at $2.5 million, down from $2.7 million in the prior quarter.
• The five-year high for Receivables was $5.8 million in Q2 2023, with the low at $2.5 million in Q2 2025.
• Average Receivables over 5 years is $3.5 million, with a median of $3.3 million recorded in 2021.
• Year-over-year, Receivables surged 8095.97% in 2021 and slumped 54.01% in 2024.
• Tracing ATHE's Receivables over 5 years: stood at $3.3 million in 2021, then rose by 2.75% to $3.4 million in 2022, then surged by 71.12% to $5.8 million in 2023, then tumbled by 54.01% to $2.7 million in 2024, then slipped by 5.32% to $2.5 million in 2025.
• The last three Receivables figures came in at $2.5 million (Q2 2025), $2.7 million (Q2 2024), and $5.8 million (Q2 2023), per Business Quant data.

Peer Comparison